Novavax Inc. (Nasdaq: NVAX) reported positive results from a Phase 2 clinical trial of its RSV F-protein vaccine in adults 60 years of age and older sending the stock price soaring $2.70 to close at $13.89.
Positive study results for Novavax
August 11, 2015 at 18:24 PM EDT
